Trimecaine

Trimecaine
Names
	IUPAC name N2,N2-Diethyl-N1-(2,4,6-trimethylphenyl)glycinamide
	Systematic IUPAC name 2-(Diethylamino)-N-(2,4,6-trimethylphenyl)acetamide
	Other names N2,N2-diethyl-N-mesitylglycinamide
Identifiers
CAS Number	616-68-2 ;
3D model ( JSmol)	Interactive image;
ChemSpider	11533;
ECHA InfoCard	100.009.535
EC Number	210-487-3;
KEGG	D08640;
MeSH	D014288
PubChem CID	12028;
UNII	IN1233R0JO ;
CompTox Dashboard (EPA)	DTXSID6048410 ;
	InChI InChI=1S/C15H24N2O/c1-6-17(7-2)10-14(18)16-15-12(4)8-11(3)9-13(15)5/h8-9H,6-7,10H2,1-5H3,(H,16,18) Key: GOZBHBFUQHMKQB-UHFFFAOYSA-N;
	SMILES CCN(CC)CC(=O)NC1=C(C=C(C=C1C)C)C;
Properties
Chemical formula	C15H24N2O
Molar mass	248.36386
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Trimecaine (systematic name (2,4,6-trimethylphenylcarbamoylmethyl)diethylammonium chloride, chemical formula C₁₅H₂₅ClN₂O) is an organic compound used as a local anesthetic and cardial antiarrhythmic. It is white crystalline powder readily soluble in water and ethanol.^[1] It is an active ingredient in products available under trademarks Mesdicain, Mesocain, Mesokain and others.^[2]

History

Trimecaine is probably a Czech discovery (in light of complex pharmacological and clinical evaluation and practical deployment) although its preparation was published by Löfgren in 1946.^[2]

Action mechanism, pharmacokinetics

Like other local anesthetics belonging in the amide group trimecaine decreases the cell membrane permeability, causes depolarization and shortens the action potential.^[3] Anesthetic effect starts within 15 minutes and remains 60–90 minutes. Its biological half-life is ca. 90 minutes. 10% of trimecaine is excreted unchanged (90% as its metabolites). It passes through the hematoencephalic and placental barriers.^[4]